Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement
04.12.23|Adiel Eithan Mustaki
The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level
